Skip to content
Head to head

Nektar Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NKTR · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

NKTR -49.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
NKTRVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price30.20515.02
Change today-7.19%-1.08%
1-year return-45.2%+22.0%
Market cap$1.03B$130.58B
52-week range30.13 – 109.00412.27 – 568.67
Valuation
P/E (TTM)-4.8833.14
P/E percentile, own 5-yr range20th99th
P/B1.226.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-9.7315.32
Net profit (TTM)$-332.91M$3.88B
Revenue (TTM)$52.19M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-20.4%+11.8%
Gross margin100.0%85.5%
Operating margin-303.6%33.1%
Net margin-339.7%30.7%
Free cash flow (TTM)$-257.49M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership110.4%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)19.8%1.9%
Analyst consensus70% buy / 30% hold (10)95% buy / 5% hold (21)
Analyst price target$138 (+356%)$624 (+21%)
StockVane view
StockVane Quant RatingE (6)C (68)
Company
Employees636,400
Founded19901989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.